These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 33976643)
1. Response to Vemurafenib in Metastatic Triple-Negative Breast Cancer Harbouring a BRAF V600E Mutation: A Case Report and Electronically Captured Patient-Reported Outcome. Pircher M; Winder T; Trojan A Case Rep Oncol; 2021; 14(1):616-621. PubMed ID: 33976643 [TBL] [Abstract][Full Text] [Related]
2. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146 [TBL] [Abstract][Full Text] [Related]
3. Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF Cho SM; Esmail A; Abdelrahim M Front Pharmacol; 2021; 12():795381. PubMed ID: 34975492 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus. Shi L; Zou Z; Ding Q; Liu Q; Zhou H; Hong X; Peng G Cancer Biol Ther; 2019; 20(4):431-434. PubMed ID: 30462564 [TBL] [Abstract][Full Text] [Related]
7. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651 [TBL] [Abstract][Full Text] [Related]
8. BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report. Peker YS; Can MF; Ozerhan IH; Yagci G; Zeybek N; Kavakli K; Gurkok S; Gozubuyuk A; Genc O; Erdem G; Ozet A; Gerek M; Peker Y Case Rep Surg; 2018; 2018():8782328. PubMed ID: 29850361 [TBL] [Abstract][Full Text] [Related]
9. Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report. Wang Z; He D; Chen C; Liu X; Ke N Front Oncol; 2021; 11():801320. PubMed ID: 35145907 [TBL] [Abstract][Full Text] [Related]
10. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229 [TBL] [Abstract][Full Text] [Related]
11. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Hong DS; Morris VK; El Osta B; Sorokin AV; Janku F; Fu S; Overman MJ; Piha-Paul S; Subbiah V; Kee B; Tsimberidou AM; Fogelman D; Bellido J; Shureiqi I; Huang H; Atkins J; Tarcic G; Sommer N; Lanman R; Meric-Bernstam F; Kopetz S Cancer Discov; 2016 Dec; 6(12):1352-1365. PubMed ID: 27729313 [TBL] [Abstract][Full Text] [Related]
13. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. Joshi M; Rice SJ; Liu X; Miller B; Belani CP PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985 [TBL] [Abstract][Full Text] [Related]
14. Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463 [No Abstract] [Full Text] [Related]
15. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib. van Tilburg CM; Selt F; Sahm F; Bächli H; Pfister SM; Witt O; Milde T Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29230924 [TBL] [Abstract][Full Text] [Related]
16. A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. Maleka A; Åström G; Byström P; Ullenhag GJ BMC Cancer; 2016 Aug; 16():634. PubMed ID: 27520988 [TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065 [TBL] [Abstract][Full Text] [Related]
18. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442 [TBL] [Abstract][Full Text] [Related]
19. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178 [TBL] [Abstract][Full Text] [Related]
20. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Ravnan MC; Matalka MS Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]